/

EPRX.TO

EUPRAXIA PHARMACEUTICALS INCClosed

9.36−0.23 −2.40%CAD

Toronto · as of Oct 14, 16:00 ET · 15m delay

Open

9.50

Prev close

9.59

Day range

9.209.68

52-week range

7.3513.08

Volume

67.13K0.89×

Mkt cap

618.45M

P/E ttm

—

Fwd P/E

-6.37

EPS ttm

-1.41

Div yield

0.00%

Earnings

—

From 52w high

−28.44%

Price Chart

Yahoo Finance · delayed

EPRX.TOOct 14, 2026O 9.50H 9.68L 9.20C 9.36−0.23 (−2.40%)Vol 67.13K

SMA 5010.46
SMA 20010.22

1Y change +11.43% since Oct 10, 2025 close540 bars loadedTimes in America/TorontoDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

EPRX.TO EUPRAXIA PHARMACEUTICALS INC · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −15.14%
1 month: −16.50%
3 months: +2.07%
6 months: −6.68%
Year to date: −9.30%
1 year: +9.09%

Valuation & ownership

Market cap: 618.45M
Enterprise value: 528.15M
P/E (ttm): —
Forward P/E: -6.37
PEG ratio: —
Price / book: 4.24
Price / sales (ttm): —
EV / EBITDA: -9.29
EPS (ttm): -1.41
EPS (forward): -1.47
Beta (5y monthly): 1.22
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 66.07M
Float: 55.67M
Short % of float: 0.29%
Short ratio (days): 1.90
Held by insiders: 12.11%
Held by institutions: 43.34%
Avg volume (3m): 75.22K
50-day average: 10.46
200-day average: 10.22
52-week change: +9.09%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 37.1
vs 50-day SMA: −10.55%
vs 200-day SMA: −8.42%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.91%
Realised vol (20d, ann.): 87.6%
From 52-week high: −28.44%
From 52-week low: +27.35%

ANR

Analyst Consensus

3 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

16.33

+74.50% implied

Low 14.00Median 17.00High 18.00

Recommendation trend

Now12 / 0 / 0
1m ago12 / 0 / 0
2m ago

DES

About EUPRAXIA PHARMACEUTICALS INC

Yahoo Finance profile

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Sector: Healthcare
Industry: Biotechnology
Employees: 49
Headquarters: Victoria, BC, Canada
Website: eupraxiapharma.com
Officers: Dr. James A. Helliwell FRCPC, M.D. CEO & Director
Mr. Alexander John Rothwell Eng., M.B.A. Chief Financial Officer
Mr. Paul Anthony Brennan B.Sc., M.Sc. Chief Corporate Development Officer
Ms. Wajida Leclerc B.A., CCP, CHRP

SEAS

Seasonality · EPRX.TO

2021–2026 · monthly returns

Strongest month Nov +10.27%Weakest month Mar −9.70%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	9.0	-1.0	-9.9	6.1	-6.8	-6.2	-3.5	-0.1	44.8	-27.9			−9.3%
2025	-1.3	28.1	-17.5	16.8	-2.7	46.8	-4.8	-0.5	10.5	-2.4	9.1	18.2	+128.8%
2024	8.9	14.0	-36.3	-13.2	-1.1	-4.1	14.0	-14.0	3.5	-7.0	44.5	-5.5	−16.0%
2023	10.1	5.5	-0.2	41.8	13.0	27.6	-11.8	4.8	-13.7	-26.8	6.7	-0.4	+47.1%
2022	-15.1	-8.7	15.3	-32.4	-5.4	-23.6	-1.9	41.0	55.4	73.0	-3.5	-4.9	+49.0%
2021				-0.4	-19.7	-3.6	-10.9	-16.7	-10.0	-19.6	-5.5	19.5	−53.2%

INSD

Insider Activity · EPRX.TO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 22, 2026	Freedman (Joseph Stuart)Director of Issuer	—	1.22M	—
Sep 22, 2026	Freedman (Joseph Stuart)Director of Issuer	—	387.3K	—
Sep 22, 2026	Freedman (Joseph Stuart)Director of Issuer	—	1.60M	—
Aug 18, 2026	Montalbano (John S.)Director of Issuer	Acquisition in the public market at price 6.82 per share.	22K	$150.04K
Jun 17, 2026	Pott (Amy)Director of Issuer	—	0	—
Jun 17, 2026	Bazemore (Robert B)Director of Issuer	—	0	—
May 4, 2026	Helliwell (James Allen)Director of Issuer	Exercise of warrants at price 0.56 per share.	150K	$83.40K
Apr 30, 2026	Tambiah (Jeyanesh)Senior Officer of Issuer	—	0	—
Mar 26, 2026	Helliwell (James Allen)Director of Issuer	Exercise of warrants at price 2.16 per share.	30K	$64.80K
Mar 26, 2026	Pimstone (Simon Neil)Director of Issuer	Acquisition in the public market at price 6.76 per share.	2.5K	$16.90K
Mar 26, 2026	Pimstone (Simon Neil)Director of Issuer	Acquisition in the public market at price 6.77 per share.	2K	$13.53K
Mar 26, 2026	Pimstone (Simon Neil)Director of Issuer	Acquisition in the public market at price 6.80 per share.	2K	$13.59K
Mar 26, 2026	Pimstone (Simon Neil)Director of Issuer	Acquisition in the public market at price 6.84 per share.	3K	$20.51K
Mar 26, 2026	Pimstone (Simon Neil)Director of Issuer	Acquisition in the public market at price 6.87 per share.	2.5K	$17.17K
Mar 17, 2026	Freedman (Joseph Stuart)Director of Issuer	Acquisition in the public market at price 7.94 per share.	1.7K	$13.50K
Mar 17, 2026	Freedman (Joseph Stuart)Director of Issuer	Acquisition in the public market at price 7.80 per share.	4.2K	$32.77K
Mar 17, 2026	Freedman (Joseph Stuart)Director of Issuer	Acquisition in the public market at price 7.40 per share.	3.9K	$28.68K
Mar 17, 2026	Freedman (Joseph Stuart)Director of Issuer	Acquisition in the public market at price 7.76 per share.	1.8K	$13.96K
Mar 17, 2026	Freedman (Joseph Stuart)Director of Issuer	Acquisition in the public market at price 7.89 per share.	1.3K	$10.26K
Mar 17, 2026	Freedman (Joseph Stuart)Director of Issuer	Acquisition in the public market at price 7.94 per share.	1.9K	$15.31K

EPRX.TO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

EPRX.TO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About EUPRAXIA PHARMACEUTICALS INC

Seasonality · EPRX.TO

Insider Activity · EPRX.TO

Congress Trades · EPRX.TO

Investors Holding EPRX.TO

Investors Holding EPRX.TO

Congress Trades · EPRX.TO

Insider Activity · EPRX.TO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About EUPRAXIA PHARMACEUTICALS INC

Financial Snapshot

Earnings & Dividends

News

Seasonality · EPRX.TO